FACTORS INFLUENCING THE OUTCOME OF THERAPEUTIC PENETRATING KERATOPLASTY FOR MYCOTIC & SUPPURATIVE KERATITIS Philip A. Thomas J.Kaliamurthy C.A.Nelson Jesudasan.

Slides:



Advertisements
Similar presentations
FUNGAL KERATITIS IN MAN Andrew Tullo Royal Eye Hospital, Manchester.
Advertisements

Case report Reporter: I2 陳鴻文.
Experience With Microbial Keratitis After Boston Type I Keratoprosthesis Implantation Cornea & Anterior Segment Services, L V Prasad Eye Institute, Hyderabad,
Therapeutic Penetrating Keratoplasty in Fungal Keratitis: Prospective Study Sonika Gupta Consultant Ophthalmology Max Eye Care New Delhi, India Author.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Mycotic Ulcer Treatment Trial Prajna NV, Krishnan T, Mascarenhas J, et al; Mycotic.
Paradox of Corneal CXL and Infectious Keratitis: To Do or Not to Do? None of the authors have any financial disclosure to make Vishal Vohra,MS (Presenting.
Amit Gupta, MS Swapnil M. Parchand, MBBS Jagat Ram, MS Arunaloke Chakrabarti, MD Amod Gupta, MS Advanced Eye Centre, Post Graduate Institute of Medical.
Comparison of Rates of Positive Cultures in Patients with Bacterial Keratitis With and Without Previous Empiric Treatment Krishna Patel 1, Shuchi B. Patel.
Physician Compliance With the HEDS Recommendation of Antiviral Prophylaxis in Patients Diagnosed With Herpetic Stromal Keratitis at KEI Sameen Zaidi M.D.
MICROBIAL KERATITIS FOLLOWING EPI-OFF CORNEAL COLLAGEN CROSSLINKING PROCEDURE Dr. K V Satyamurthy Dr. Jaysheel V N Cornea-Refractive Surgery Dept MM Joshi.
Comparison of Bacterial Etiology of Infectious Corneal Ulcers in Contact Lens Wearers and Non-Contact Lens Wearers at the University of Chicago Shuchi.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Corticosteroids to Treat Bacterial Keratitis Ray KJ, Srinivasan M, Mascarenhas.
Long term Follow-up of PK cases with herpetic Leukomas, treated with topical Acyclovir and steroids WORLD CORNEA CONGRESS VII 2015 Ramon Naranjo-Tackman,MD.
Are topical NSAIDs a safe and effective treatment for Corneal Abrasions? Department of Emergency Medicine University of Pennsylvania Health System Andrew.
Outbreak of Post-LASIK Infectious Keratitis from Single Laser Center Takefumi Yamaguchi 1, Yoshiko Hori-Komai 1, Hiroko Bissen-Miyajima 2, Yukihiro Matsumoto.
Antibiotic Susceptibilities in Patients With Contact Lens Associated Microbial Keratitis Jimmy Lim 1, Muhammad A. Ismail 2 Eileen Sim 2, Timothy Barkham.
EVALUATION OF INTRA-CORNEAL INJECTION OF 5% NATAMYCIN FOR THE TREATMENT OF FUSARIUM KERATITIS Fani Segev MD, Guy Tam MD, Yossi Paitan PhD, Dvora Kidron.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Multi-Drug Resistant Pseudomonas Keratitis Clinical Characteristics and Associated Features Jayesh Vazirani Merle Fernandes L V Prasad Eye Institute Visakhapatnam,
Bilateral Corneal Trophic Ulcers and Subsequent Infectious Keratitis in a Patient with Graft-versus-host Disease Yonca Aydın Akova, MD Bayındır Hospital,
C-Reactive Protein: a Prognosis Factor for Septic Patients Systematic Review and Meta-analysis Introduction to Medicine – 1 st Semester Class 4, First.
Dr. Revathi Rajaraman Aravind Eye Hospital Coimbatore
Epidemiology of Infectious Corneal Ulcers at Tertiary Centers in Vancouver, BC Karolien Termote, Aaron W Joe, Andrea L Butler, Simon J Holland, Sonia.
Management of Methicillin- Resistant Staphylococcus Aureus Keratitis in Post-surgical Patients: Two Case Reports Sujata P. Prabhu, MD and Timothy Y. Chou,
Microsporidial Stromal Keratitis : Dilemma in Clinical Diagnosis Swapnali Sabhapandit, MS Prashant Garg, MD Somasheila Murthy, MS Geeta K Vemuganti, MD.
Somasheila I. Murthy, Prashant Garg, Pravin K. Vaddavalli
BACTERIAL KERATITIS AND ASSOCIATED ENDOPHTHALMITIS Dermot Cassidy FRANZCO, Paul Connell FRCSI, Penelope Allen FRANZCO, Rasik Vajpayee MS, FRCS(Edin), FRANZCO.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Evaluation of Bactericidal and Fungicidal Activity of Riboflavin Plus UVA Irradiation for Corneal CXL Authors Ashok Sharma, Cornea Centre, Chandigarh,
OCULAR HYPERTENSION AFTER PENETRATING KERATOPLASTY F Orucov, E Strassman, D Landau, J Frucht-Pery and A Solomon, Department of Ophthalmology, Hadassah-Hebrew.
Incidence of hospitalisations in both groups Incidence of documented infections Abstract Problem statement: Patients on cancer chemotherapy are at substantial.
Outcome of therapeutic keratoplasty in fungal keratitis Sonika Gupta, MS Assistant Professor, GMCH, Chandigarh, India Author has no financial interest.
Glaucoma and Penetrating Keratoplasty : Incidence, Risk Factors, and Outcomes Sonika Gupta Consultant Ophthalmology Max Eye Care New Delhi, India Author.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Opportunistic Pathogens –Aspergillus species. Aspergillosis is an infection caused by Aspergillus, a common mold that lives indoors and outdoors. Most.
Indications for and Outcomes of Therapeutic Penetrating Keratoplasty Sonika Gupta Consultant Ophthalmology Max Eye Care New Delhi, India Author has no.
Post Keratoplasty Atopic Sclerokeratitis (PKAS) after Deep Anterior Lamellar Keratoplasty (DALK). Sharmina R Khan William H Ayliffe Mayday University Hospital,
Paecilomyces Fungal Keratitis: Combining Multiple Strategies to Improve the Outcome of Severe, Pesticide-Associated Fungal Keratitis Jonathan Etter, MD,
Management of Mycotic Keratitis
Clinical outcome of DALK in Keratoconus – A one year follow up
E-Poster Price Vision Group & Cornea Research Foundation of America Descemet - Stripping Endothelial Keratoplasty :Survival Outcomes in Eyes with Pre-
RELEVANCERELEVANCE Is the objective of the article on harm similar to your clinical dilemma? Yes, the article’s objective is similar to the clinical dilemma.
Predisposing Factors, Microbial Characteristics, and Clinical Outcome of Microbial Keratitis in Hong Kong: A 10-Year Experience Alex LK Ng, Ian YH Wong.
How To Design a Clinical Trial
1 Observations from Past Approvals for Acute Bacterial Sinusitis Janice Pohlman, M.D. AIDAC Meeting, October 29, 2003.
The Etiologic Diagnosis of Corneal Ulcers at a Tertiary Eye Center in Kathmandu, Nepal. Michael R. Feilmeier, MD Geoffrey C. Tabin, MD Kavitha R. Sivaraman,
Update on Infectious Keratitis after Refractive Surgery
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Daniel D. Hayes, MD1; Carolyn Y. Shih, MD1; David C
ID: 287 Fusarium keratitis in a tertiary eye care centre in India Sujata Das, MS, FRCS Savitri Sharma, MD Samir Mahapatra, MS Srikant K Sahu, MS L V Prasad.
Incidence and outcomes of Pigmented versus Nonpigmented fungal keratitis - A Retrospective analysis Dr. Thiruvengada Krishnan, M.D. Aravind Eye Hospital.
Elmira Baghdasaryan1,2, M.D. Sophie X. Deng1, M.D., Ph.D.
Yonca Aydin Akova MD, Leyla Erkanli Asena MD
The authors have no conflicting interest in the subject matter of this poster. In Vivo Evaluation of DSAEK Interface with Scanning- Laser Confocal Microscopy.
A Case of Beauveria Bassiana Keratitis Confirmed by Gene Sequencing Sung-Dong Chang, M.D., Jong-Hwa Jun, M.D. Department of Ophthalmology, School of Medicine,
1 A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital DIABETES Care; Aug 2006; 29,8 : FM R1 임혜원.
Anita Panda Rakhi Kusumesh Murugesan Vanathi Tushar Agarwal S Khokhar Cornea and Refractive Surgery Services Dr Rajendra Prasad Centre for Ophthalmic Sciences.
Fungal Peritonitis (FP) Constantinos J. Stefanidis “P. and A. Kyriakou” Children’s Hospital Athens, Greece.
Varsha Rathi DO, P K Vaddavalli MS, S Murthy MS, V S Sangwan, MS
How To Design a Clinical Trial
Collagen Cross-Linking with Photoactivated Riboflavin (PACK-CXL) for the Treatment of Advanced Infectious Keratitis with Corneal Melting Ophthalmology.
ANTI-MICROBIAL USAGE IN THE COMMUNITY AND RESISTANCE IN E.COLI
Dr. Sandeep Arora FRCS Dr Ashish Nagpal FRCS
CORNEAL INFECTIONS 1. Bacterial keratitis 2. Fungal keratitis
CORNEAL PERFORATION AFTER CROSSLINKING TREATMENT FOR KERATOCONUS
JAMA Ophthalmology Journal Club Slides: Effect of Oral Voriconazole on Fungal Keratitis Prajna NV, TKrishnan T, Rajaraman R, et al; Mycotic Ulcer Treatment.
H Nayak, A Patel, S Gudsoorkar, V Kumar University Hospital Wales
Authors have no financial interest.
Presentation transcript:

FACTORS INFLUENCING THE OUTCOME OF THERAPEUTIC PENETRATING KERATOPLASTY FOR MYCOTIC & SUPPURATIVE KERATITIS Philip A. Thomas J.Kaliamurthy C.A.Nelson Jesudasan Institute of Ophthalmology Joseph Eye Hospital Tiruchirapalli Tamilnadu, INDIA

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis Microbial keratitis -- loss of corneal epithelium -- underlying stromal infiltrates & suppuration -- signs of inflammation -- hypopyon + Microbial keratitis due to bacteria, fungi, protozoa, viruses For successful management -- prompt diagnosis -- immediate institution of appropriate anti-microbial therapy.

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis  Initial treatment of suppurative (non-viral) keratitis: -- cefazolin / cefuroxime + gentamicin / tobramycin -- fluoroquinolone monotherapy: (moxifloxacin currently used widely for monotherapy of suppurative keratitis  Treatment of suspected fungal keratitis --topical natamycin(5%), itraconazole(1%), voriconazole (1%) --oral ketoconazole, fluconazole, itraconazole, voriconazole  To evaluate factors leading to the need for therapeutic penetrating keratoplasty in suppurative and mycotic keratitis.

FACTORS INFLUENCING THE OUTCOME OF THERAPEUTIC PENETRATING KERATOPLASTY FOR MYCOTIC & SUPPURATIVE KERATITIS  Prospective study from Jul to Dec. 2011(30 months)  Patients with suppurative (suspected microbial) keratitis  Inclusion criteria -- Informed consent provided -- Loss of corneal epithelium with clinical evidence of infection, with/without hypopyon  Exclusion criteria -- Consent not given for investigation or treatment -- Incomplete follow-up -- Had prior treatment

FACTORS INFLUENCING THE OUTCOME OF THERAPEUTIC PENETRATING KERATOPLASTY FOR MYCOTIC & SUPPURATIVE KERATITIS  Examination done at slit-lamp; clinical features noted & drawing made for patient records  Length of slit-beam used to assess vertical diameter, then turned 90 degrees to assess horizontal diameter  Slit-beam parallelo- piped; depth of ulceration & infiltrate graded subjectively  Standard photographs taken to check qualitative findings & grading of response  Repeatability studies performed to ensure uniformity in grading characteristics

FACTORS INFLUENCING THE OUTCOME OF THERAPEUTIC PENETRATING KERATOPLASTY FOR MYCOTIC & SUPPURATIVE KERATITIS MICROBIOLOGICAL DIAGNOSIS  Multiple scrapings from ulcer  Inoculation as `C` streaks onto solid media to cultivate bacteria, fungi and acanthamoebae: -- sheep blood agar -- Sabouraud dextrose agar -- non-nutrient agar with Escherichia coli overlay  Material on slide for microscopic examination (LPCB, Gram, Giemsa) Growth on culture considered significant if :  the same organisms isolated on the `C’ streaks of multiple media  growth on one medium with positive microscopy

FACTORS INFLUENCING THE OUTCOME OF THERAPEUTIC PENETRATING KERATOPLASTY FOR MYCOTIC & SUPPURATIVE KERATITIS  patients with suspected bacterial keratitis or keratitis of unknown etiology received hourly topical moxifloxacin (0.3%)  patients with suspected mycotic keratitis received hourly topical moxifloxacin and natamycin (5%). Hourly topical drops during day; once every three hours at night Oral analgesics & cycloplegics; anti-glaucoma agents if needed Dacryocystectomy & dacryocysto-rhinostomy if required Patients examined daily during 21 days of study period  TPK was performed when medical therapy failed and the eye was deemed to be at risk of serious complications.

FACTORS INFLUENCING THE OUTCOME OF THERAPEUTIC PENETRATING KERATOPLASTY FOR MYCOTIC & SUPPURATIVE KERATITIS CATEGORIES OF CLINICAL OUTCOMES Treatment success Complete healing of the ulcer within 21 days Healing Progressive healing but incomplete ulcer epithelialisation at 21 st day Indolent ulceration Persistent epithelial defect unchanged in size > 5 days of treatment Progression Increase in ulcer size or infiltrate necessitating other medical therapy Therapeutic penetrating keratoplasty required

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis Statistical analysis Analysis of putative factors influencing outcome of primary medical therapy were compared among groups Univariate (crude) analysis was performed to identify important risk factors A p-value of <0.05 was considered statistically significant

Demographic &clinical characteristics of 480 patients satisfying all criteria Variable N= 480(%) Gender (male) Age 0-20 years years years >60 years Microbial aetiology Bacteria only Fungi only Mixed (bacteria & fungi) Acanthamoeba No growth Clinical Features Duration >15 days Ulcer >6mm Ulcer depth >50% Hypopyon present (52.7%) (11%) (37%) (41%) (11%) (21.8%) (34.9%) (5.3%) (1.1%) (31.4%) (6.9%) (11.6%) (32.2%) (41.1%)

TYPE OF PRIMARY TREATMENT AS A POSSIBLE DETERMINANT OF OUTCOME Statistical analysis: p < Outcome of microbial keratitis Primary Treatment Regimen Total Moxifloxacin only Moxifloxacin and natamycin Other combinations Success 107 (48%) 104 (53%) 34 (57%) 245 (51%) Healing 058 (26%) 043 (22%) 03 (05%) 104 (22%) Indolent ulceration 021 (09%) 018 (09%) 04 (07%) 043 (09%) Progressed 027 (12%) 020 (10%) 7 (12%) 054 (11%) TPK 011 (5%) 011 (06%) 12 (19%) 034(7%)

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis Variables that possibly influenced the outcome of therapy A) Gender 252 male 228 female 181(72%)-favorable response 164(72%)- favorable response B) Age AgeFavorable response % exhibiting complete resolution % with progression of keratitis % 63% (High) 10% (Low) % Above 6049% 31% (Low) 31% (high)

C) Duration of symptoms No of DaysFavorable response 1 to 1574% 16 to 30 53% More than 30 days 33% Significant difference Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis Variables that possibly influenced the outcome of therapy

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis TPK was done for: -- seven of 104 bacterial keratitis patients (7%) of 167 mycotic keratitis patients (7%) -- three of 26 (12%) patients with mixed mycotic-bacterial keratitis of 183 (7%) patients with other or unknown causes of keratitis

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis TPK was done for: -- five of 83 patients with keratitis due to Fusarium spp. (6%) -- three of 27 patients with keratitis due to Aspergillus flavus(11%) -- one of nine patients with keratitis due to Aspergillus fumigatus -- one of 18 patients with keratitis due to other or unidentified fungal species (6%)

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis Significant Predictors for Progression of Keratitis Greatest or least diameter of corneal ulceration exceeding 6mm Depth of ulceration exceeding 50% Depth of infiltration exceeding 60% The presence of a hypopyon Patient age exceeding 40yrs Duration of symptoms exceeding 15 days Mixed bacterial-fungal growth

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis Significant Predictors for the need for TPK (based on univariate analysis) 1. Duration of symptoms > 15 days (P < ) 2. Smallest or largest ulcer diameter > 6 mm (P = 0.002) 3. Ulcer depth > 50% (P < ) 4. Infiltrate depth > 60% (P = 0.002) 5. Any growth in culture (P < ) 6. These factors were significantly more frequently associated with TPK being performed than duration of symptoms ≤ 15 days, ulcer diameter ≤ 6 mm, ulcer depth ≤ 50%, infiltrate depth ≤ 60%& no growth in culture

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis Xie et al., Br J Ophthalmol 2001; 85: Retrospective analysis of 108 cases of severe mycotic keratitis -- Graft remained clear in 80% of patients Shi et al., Ophthalmology 2010; 117: Retrospective interventional case series (614 patients) (6.3%) patients experienced recurrences -- Higher rates of recurrences in those with : pre-operative hypopyon corneal peforation infection extending up to the limbus

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis Yalniz-Akkaya et al., Int Ophthalmol 2015; 35: Retrospective analysis of 24 eyes with keratitis (follow-up 22 months) -- Graft remained clear in 93 % of patients with infective keratitis & 78% of those with non-infective keratitis Ti TE et al., Am J Ophthalmol 2007; 114: Retrospective interventional case series (92 consecutive patients who had undergone TPK) -- Fusarium spp. accounted for 32.3% of the fungal isolates patients failed therapy of the 15 patients who had failed TPKs suffered from fungal keratitis

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis SUMMARY 480 patients with suspected microbial keratitis 420 pts. received primary topical ciprofloxacin therapy, alone or in combination with natamycin -- Treatment success or healing in 73 % -- Progression of keratitis or need for TPK occurred in 18 % Patient gender not a significant determinant of response

Factors influencing the outcome of therapeutic penetrating keratoplasty for mycotic & suppurative keratitis SUMMARY Factors serving as significant predictors of an unfavourable outcome of mycotic or suppurative keratitis, necessitating TPK included: -- large and/or deep ulcers --a prolonged duration of symptoms. Primary therapy with topical moxifloxacin, alone or in combination with natamycin, appears to be effective therapy in a high percentage of patients.